Citation Impact
Citing Papers
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
The IFITM Proteins Inhibit HIV-1 Infection
2010
Independent Associations of Bacterial Vaginosis and Chlamydia trachomatis Infection With Adverse Pregnancy Outcome
1986
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
X4 and R5 HIV-1 Have Distinct Post-entry Requirements for Uracil DNA Glycosylase during Infection of Primary Cells
2010 StandoutNobel
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
2000 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
2000 Standout
Association between Bacterial Vaginosis and Preterm Delivery of a Low-Birth-Weight Infant
1995 Standout
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
2007
HIV Entry and Its Inhibition
1998
Chemokines — Chemotactic Cytokines That Mediate Inflammation
1998 Standout
Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution
1998 StandoutNature
Host factors and the pathogenesis of HIV-induced disease
1996 Nature
Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders
2008
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
1997
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
2003 StandoutNature
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects
2005
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
1996 StandoutNature
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo
2006 StandoutNobel
Core Structure of gp41 from the HIV Envelope Glycoprotein
1997 Standout
Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection
1996 Standout
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
1997 Standout
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene
1998 StandoutNobel
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
2001 StandoutScience
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Antibody neutralization and escape by HIV-1
2003 StandoutNature
Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis
1998 StandoutNature
DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells
2000 Standout
Genetic Subtypes of HIV Type 1 and HIV Type 2 Strains in Commercial Sex Workers from Bamako, Mali
1998
HIV as the cause of AIDS
1996 StandoutNobel
Uncomplicated Urinary Tract Infection
2012 Standout
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
2009
Synthetic glycopeptides and glycoproteins as tools for biology
2004 StandoutNobel
Towards improvements in molecular tools for diagnosis and management of HIV infections
1999 StandoutNobel
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
2008 StandoutNobel
Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis
2009 Standout
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor
1997 StandoutNatureNobel
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
1996 StandoutNature
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
1999
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
2004 StandoutNobel
Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem
2017
Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold
2011 StandoutScienceNobel
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
1995
Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
1994 Science
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies
2004
Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and Complications
1983 Standout
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
1995
Ablation of the Complementarity-Determining Region H3 Apex of the Anti-HIV-1 Broadly Neutralizing Antibody 2F5 Abrogates Neutralizing Capacity without Affecting Core Epitope Binding
2010
Bacteriology and ultrastructure of the bladder in patients with urinary tract infections
1985
Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
2002
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism
1997
Efficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1
1999
Antigenic conservation and immunogenicity of the HIV coreceptor binding site
2005
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
1997
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Homogeneous Glycopeptides and Glycoproteins for Biological Investigation
2002 StandoutNobel
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
1995
Membrane Fusion and Exocytosis
1999 StandoutNobel
Chemoselective Elaboration of O-Linked Glycopeptide Mimetics by Alkylation of 3-ThioGalNAc
2001 StandoutNobel
Glycosylation Affects both the Three-Dimensional Structure and Antibody Binding Properties of the HIV-1IIIBGP120 Peptide RP135
1997
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage
1998 StandoutNobel
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
1997
Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization
2001
Rapid Infection of Oral Mucosal-Associated Lymphoid Tissue with Simian Immunodeficiency Virus
1999 StandoutScienceNobel
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
1996 StandoutScience
Diagnosis of Coliform Infection in Acutely Dysuric Women
1982
Induction and Evasion of Host Defenses by Type 1-Piliated Uropathogenic Escherichia coli
1998 StandoutScience
Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies
1999
Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1
1998
Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia
1997 StandoutScience
Endocarditis Due to Rare and Fastidious Bacteria
2001 Standout
Patient-Initiated Treatment of Uncomplicated Recurrent Urinary Tract Infections in Young Women
2001
Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4 + T Cells
1997 Science
Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes
1999
Enhancement of Antibodies to the Human Immunodeficiency Virus Type 1 Envelope by Using the Molecular Adjuvant C3d
2003
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin
1995
Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells
1998 StandoutNobel
Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants
2001
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Prospects for the Future
2002 StandoutScienceNobel
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
1995
Regulation of membrane fusion by the membrane-proximal coil of the t-SNARE during zippering of SNAREpins
2002 StandoutNobel
Works of K Wagner being referenced
Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1
1996
Phase I Trial of Interferon Alfa-n3 in Early-Stage Human Immunodeficiency Virus Type 1 Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity
1996
Clinical Manifestations of Kingella kingae Infections: Case Report and Review
1989
Mucosal Immune Responses in Four Distinct Compartments of Women Infected with Human Immunodeficiency Virus Type 1: A Comparison by Site and Correlation with Clinical Information
1997
Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype
1994
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function
1997
Causes of the Acute Urethral Syndrome in Women
1980
Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals
1996